Jun Takeoka¹, Tomomi Oka², Kyoka Fujita¹, Satoshi Kurahashi¹, Naohiro Toda^1,4, Toshiyuki Komiya^1,4 and Masaaki Fujita^3,5*

¹Division of Nephrology, Kansai Electric Power Hospital, Osaka, Japan

²Division of Hematology, Kansai Electric Power Hospital, Osaka, Japan

³Division of Clinical Immunology and Rheumatology, Kansai Electric Power Hospital, Osaka, Japan

⁴Division of Renal Disease and Blood Purification, Kansai Electric Power Medical Research Institute, Osaka, Japan 

⁵Department of Infectious Diseases, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan

^*Corresponding author: Masaaki Fujita, Division of Clinical Immunology and Rheumatology, Kansai Electric Power Hospital, Osaka, Japan, 2-1-7 Fukushima, Fukushima-ku, Osaka, 553-0003 Japan. E-mail: fujita.masaaki@e3.kepco.co.jp

Received: October 25, 2021; Accepted: November 02, 2021; Published: November 14, 2021

Citation: Fujita M, Takeoka J, Oka T, et al. Treatment of Secondary Immune Thrombocytopenia with Tacrolimus. Clin Image Case Rep J. 2021; 3(9): 189.